Oramed Pharmaceuticals Inc.
General ticker "ORMP" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $93.6M (TTM average)
Oramed Pharmaceuticals Inc. follows the US Stock Market performance with the rate: 37.3%.
Estimated limits based on current volatility of 3.9%: low 3.46$, high 3.74$
Factors to consider:
- Total employees count: 15 (-11.8%) as of 2023
- Top business risk factors: Strategic risks and growth management, Labor/talent shortage/retention, Operational and conduct risks, Third-party risks, Market competition
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.57$, 3.35$]
- 2025-12-31 to 2026-12-31 estimated range: [1.62$, 3.45$]
Financial Metrics affecting the ORMP estimates:
- Positive: with PPE of -14.1 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -8.62 <= 0.04
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 94.20 > 64.17
- Positive: Interest expense per share per price, % of 0.87 <= 3.31
- Positive: Investing cash flow per share per price, % of 108.49 > -0.62
- Positive: Inventory ratio change, % of 0 <= 0
Short-term ORMP quotes
Long-term ORMP plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $2.70MM | $1.34MM | $0.00MM |
| Operating Expenses | $43.30MM | $17.11MM | $12.78MM |
| Operating Income | $-40.60MM | $-15.77MM | $-12.78MM |
| Non-Operating Income | $2.93MM | $20.86MM | $-3.14MM |
| Interest Expense | $0.00MM | $2.04MM | $0.85MM |
| R&D Expense | $27.64MM | $8.97MM | $6.32MM |
| Income(Loss) | $-37.66MM | $5.09MM | $-15.92MM |
| Taxes | $0.10MM | $0.00MM | $3.18MM |
| Profit(Loss)* | $-36.56MM | $5.53MM | $-19.15MM |
| Stockholders Equity | $151.81MM | $163.82MM | $146.26MM |
| Assets | $161.64MM | $220.55MM | $155.28MM |
| Operating Cash Flow | $-27.92MM | $-10.29MM | $-8.41MM |
| Capital expenditure | $0.50MM | $0.25MM | $0.02MM |
| Investing Cash Flow | $30.21MM | $-73.04MM | $105.82MM |
| Financing Cash Flow | $10.78MM | $51.98MM | $-52.04MM |
| Earnings Per Share** | $-0.94 | $0.14 | $-0.47 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.